Agilent is committed to maintaining Varian’s tradition of excellence in dissolution and establishing a new standard for pharmaceutical companies and other firms operating in a global marketplace, said Frank Riba, Agilent business manager, Dissolution Division. The new 708-DS Dissolution Apparatus yields the sample-to-sample consistency that is critical for scientists assessing batch-to-batch performance, bioequivalency and other characteristics of their compounds.
The 708-DS Dissolution Apparatus is available as a basic manual model and in a variety of automated configurations for high-throughput online sampling and online UV analysis. The apparatus allows for several advanced usage options, including temperature monitoring, automated dosage delivery and in-situ fiber optic analysis. Customized add-ons allow a variety of dosage types to be analyzed on the same apparatus.
The design of the 708-DS Dissolution Apparatus conforms to internationally harmonized pharmacopeia specifications for basket, paddle, rotating cylinder, intrinsic and paddle-over-disk configurations. The apparatus can test tablets, capsules and a wide variety of other dosage forms.
In addition to the dissolution apparatus hardware and software, Agilent offers users peace of mind by providing high-quality service for the DS-708 Dissolution Apparatus around the globe, including:
* qualification documentation for the entire system;
* trained chemists to perform the installation and qualification;
* standard operating procedure templates;
* technical support for drug release methods, equipment and regulatory questions; and
* sponsorship for the vendor-neutral online Dissolution Discussion Group forum.